Adiponectin, also known as ADIPOQ, AdipoQ, or Acrp30, is an endogenous hormone predominantly produced by adipose tissue. It belongs to the chemical class of proteins and is a significant component of the metabolic and circadian hormone category. Adiponectin circulates in the bloodstream and is involved in various metabolic processes. It is a 244-amino acid protein that forms multimers, which are crucial for its biological activity. Researchers have extensively studied adiponectin due to its role in metabolic regulation and its potential therapeutic implications. Adiponectin plays a critical role in regulating glucose levels and fatty acid breakdown. It is inversely correlated with body fat percentage in adults, and lower levels are associated with obesity, type 2 diabetes, and cardiovascular diseases. Researchers have found that adiponectin enhances insulin sensitivity and exhibits anti-inflammatory properties. It is also involved in energy homeostasis and has been a focus of research in metabolic syndrome and related disorders. The mechanism of action of adiponectin involves binding to its receptors, AdipoR1 and AdipoR2, which are widely expressed in various tissues. Activation of these receptors triggers AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor alpha (PPAR-α) pathways, leading to increased fatty acid oxidation and improved insulin sensitivity. Researchers have observed that these pathways are crucial for the hormone's metabolic effects. The pharmacokinetic properties of adiponectin are not fully characterized, but it is known to have a relatively short circulating half-life, estimated to be around 70 minutes. Its metabolism and bioavailability by different routes are not well-documented, as it is primarily studied in its endogenous form. Clinical use of adiponectin as a therapeutic agent is still under investigation, and it is not currently approved for any specific medical treatment. Researchers are exploring its potential in treating metabolic disorders, but it remains in the research phase without regulatory approval for clinical use.